Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score
暂无分享,去创建一个
Dan Wang | Song Liu | Mateusz Opyrchal | Song Liu | T. Khoury | M. Opyrchal | Dan Wang | Thaer Khoury | Xiao Huang | Xiwei Chen | Xiao Huang | Xiwei Chen
[1] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[2] G M Clark,et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jorge S Reis-Filho,et al. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.
[4] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[5] Song Liu,et al. Oncotype DX RT-qPCR Assay for ER and PR Correlation With IHC: A Study of 3 Different Clones , 2015, Applied immunohistochemistry & molecular morphology : AIMM.
[6] Scott D. Brown,et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.
[7] A. Gown,et al. Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? , 2011, Breast Cancer Research and Treatment.
[8] D. Dabbs,et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Kevin Coombes,et al. Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy , 2005, Clinical Cancer Research.
[10] T. Yamanaka,et al. Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population , 2010, Cancer.
[11] S. Shak,et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.
[12] Rohit Bhargava,et al. Histopathologic variables predict Oncotype DX™ Recurrence Score , 2008, Modern Pathology.
[13] B. Kreike,et al. The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type , 2010, The Journal of pathology.
[14] Josh J. Carlson,et al. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis , 2013, Breast Cancer Research and Treatment.
[15] N. Esposito,et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas , 2012, Modern Pathology.
[16] S. Pinder,et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma , 1995, Histopathology.
[17] R. Gray,et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M J Gaffey,et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. , 1995, American journal of clinical pathology.
[19] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[21] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[22] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] A. Nichol,et al. Improving screening mammography return rates in overdue women: A randomized study of signed reminder letters from family physicians. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Dabbs,et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis , 2013, Modern Pathology.
[26] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.